Bruno Quesnel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5536492/publications.pdf

Version: 2024-02-01

250 papers	12,049 citations	31976 53 h-index	30922 102 g-index
255 all docs	255 docs citations	255 times ranked	13022 citing authors

#	Article	IF	Citations
1	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-Î³ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 2007, 110, 296-304.	1.4	546
2	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 2011, 25, 1147-1152.	7.2	430
3	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 2011, 118, 3765-3776.	1.4	424
4	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. Journal of Clinical Oncology, 2011, 29, 3322-3327.	1.6	421
5	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematology,the, 2016, 3, e186-e195.	4.6	359
6	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 2011, 117, 403-411.	1.4	348
7	Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 2006, 20, 965-970.	7.2	340
8	Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression. Blood, 1998, 91, 2985-2990.	1.4	337
9	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	27.0	335
10	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	1.4	264
11	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe dâ€™Etude des Lymphomes de lâ€™Adulte. Journal of Clinical Oncology, 2007, 25, 787-792.	1.6	239
12	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	3.5	234
13	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 2010, 24, 1094-1096.	7.2	225
14	MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 2013, 121, 4504-4511.	1.4	214
15	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, 2015, 125, 3618-3626.	1.4	197
16	Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma. Journal of Clinical Oncology, 2002, 20, 2472-2479.	1.6	194
17	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	1.6	189
18	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	12.8	177

#	Article	IF	Citations
19	Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature.. Journal of Clinical Oncology, 1993, 11, 2370-2379.	1.6	173
20	Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des MyÃ©lodysplasies (GFM). Journal of Clinical Oncology, 2021, 39, 1575-1583.	1.6	169
21	In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood, 2004, 104, 2124-2133.	1.4	156
22	Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia, 2006, 20, 35-41.	7.2	149
23	In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunology, Immunotherapy, 2010, 59, 1839-1849.	4.2	143
24	Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer, 2020, 2, zcaa002.	3.1	142
25	Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood, 2010, 116, 3735-3742.	1.4	141
26	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. Journal of Clinical Oncology, 2009, 27, 4747-4753.	1.6	123
27	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135.	1.4	121
28	NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood, 2005, 105, 2428-2435.	1.4	112
29	Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia, 2005, 19, 792-798.	7.2	108
30	RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death and Disease, 2014, 5, e1384-e1384.	6.3	105
31	Genomic Landscape of CXCR4 Mutations in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2016, 22, 1480-1488.	7.0	102
32	Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 1998, 91, 2985-90.	1.4	96
33	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	1.8	92
34	Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patientsâ€™ sera by HPLC and is inducible by IFN-î³. Leukemia Research, 2009, 33, 490-494.	0.8	91
35	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. American Journal of Hematology, 2014, 89, 410-416.	4.1	91
36	Targeting MYC in multiple myeloma. Leukemia, 2018, 32, 1295-1306.	7.2	89

#	Article	IF	Citations
37	Tumor dormancy and immunoescape. Apmis, 2008, 116, 685-694.	2.0	86
38	p16 INK4a andp15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 2001, 98, 244-246.	1.4	77
39	Effect of priming with granulocyteâ€“macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia, 2007, 21, 453-461.	7.2	74
40	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clinical Pharmacokinetics, 2016, 55, 397-405.	3.5	72
41	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	5.2	72
42	<scp>MYD</scp>88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. British Journal of Haematology, 2014, 167, 506-513.	2.5	71
43	Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death and Disease, 2018, 9, 325.	6.3	71
44	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	1.6	68
45	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 2006, 20, 2067-2070.	7.2	64
46	TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2017, 23, 6325-6335.	7.0	64
47	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des MyÃ©lodysplasies (GFM). Blood, 2019, 134, 677-677.	1.4	62
48	Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 1994, 8, 1342-9.	7.2	61
49	Over-expression of the MDM2gene is found in some cases of haematological malignancies. British Journal of Haematology, 1994, 88, 415-418.	2.5	60
50	Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. Oncotarget, 2016, 7, 39473-39485.	1.8	58
51	Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Therapy, 1999, 6, 314-320.	4.5	57
52	Î³-Ray irradiation induces B7.1 expression in myeloid leukaemic cells. British Journal of Haematology, 2000, 108, 825-831.	2.5	57
53	The PI3K/AKT Signaling Pathway Controls the Quiescence of the Low-Rhodamine123-Retention Cell Compartment Enriched for Melanoma Stem Cell Activity. Stem Cells, 2013, 31, 641-651.	3.2	57
54	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	1.4	57

#	Article	IF	Citations
55	PD-1/PD-L1 binding studies using microscale thermophoresis. Scientific Reports, 2017, 7, 17623.	3.3	56
56	Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers, 2021, 13, 3034.	3.7	56
57	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood, 2017, 130, 832-835.	1.4	55
58	Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia, 2004, 18, 1223-1230.	7.2	54
59	MDM2 gene amplification in human breast cancer. European Journal of Cancer, 1994, 30, 982-984.	2.8	53
60	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	12.4	53
61	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, 1754-1762.	1.4	52
62	P15^{INK4b}Gene Methylation and Myelodysplastic Syndromes. Leukemia and Lymphoma, 1999, 35, 437-443.	1.3	51
63	Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leukemia and Lymphoma, 2012, 53, 1068-1076.	1.3	50
64	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 2012, 120, 5084-5085.	1.4	50
65	Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells. PLoS ONE, 2011, 6, e21924.	2.5	49
66	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. British Journal of Haematology, 2012, 157, 764-766.	2.5	49
67	Outcome of older patients with acute myeloid leukemia in first relapse. American Journal of Hematology, 2013, 88, 758-764.	4.1	49
68	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in Oncology, 2018, 8, 665.	2.8	47
69	Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1. Cancer Research, 2007, 67, 4491-4498.	0.9	46
70	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research, 2015, 39, 501-504.	0.8	46
71	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia, 2002, 16, 1637-1644.	7.2	45
72	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leukemia Research, 2013, 37, 637-640.	0.8	45

#	Article	IF	Citations
73	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	4.1	45
74	Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood, 2010, 115, 78-88.	1.4	44
75	Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplantation, 2000, 25, 251-256.	2.4	43
76	Transduction of Bone Marrow Cells by the AdZ.F(pK7) Modified Adenovirus Demonstrates Preferential Gene Transfer in Myeloma Cells. Human Gene Therapy, 1999, 10, 2709-2717.	2.7	42
77	Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy, 2000, 7, 1312-1316.	4.5	42
78	BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia, 2008, 22, 791-799.	7.2	41
79	Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.. Blood, 2007, 110, 249-249.	1.4	41
80	Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines. Phytochemistry, 2008, 69, 2979-2983.	2.9	40
81	Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis, 2009, 204, e4-e14.	0.8	40
82	GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells. Oncogene, 2012, 31, 1419-1430.	5.9	40
83	Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. British Journal of Haematology, 1994, 87, 61-67.	2.5	38
84	Dormant tumor cells as a therapeutic target?. Cancer Letters, 2008, 267, 10-17.	7.2	38
85	Pathologic and Clinical Features of 77 Hodgkin's Lymphoma Patients Treated in a Lymphoma Protocol (LNH87). American Journal of Surgical Pathology, 2001, 25, 297-306.	3.7	37
86	Analysis of p16 gene deletion and point mutation in breast carcinoma. British Journal of Cancer, 1995, 72, 351-353.	6.4	36
87	CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. Cancer Research, 2015, 75, 3902-3911.	0.9	36
88	Familial myeloid malignancies with germline TET2 mutation. Leukemia, 2020, 34, 1450-1453.	7.2	36
89	Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia, 2011, 25, 1207-1209.	7.2	35
90	A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. Experimental Hematology, 2010, 38, 124-131.e4.	0.4	34

#	Article	IF	Citations
91	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia, 2017, 31, 555-564.	7.2	34
92	Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood, 2012, 119, 6172-6173.	1.4	33
93	Outcomes in <scp>RBC</scp> transfusionâ€dependent patients with <scp>L</scp>owâ€/<scp>I</scp>ntermediateâ€1â€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <scp>MDS</scp>â€004 study. European Journal of Haematology, 2014, 93, 429-438.	2.2	32
94	B7â€H3 protein expression in acute myeloid leukemia. Cancer Medicine, 2015, 4, 1879-1883.	2.8	32
95	The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases. Leukemia and Lymphoma, 1995, 18, 497-503.	1.3	30
96	Longâ€term followâ€up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	4.1	30
97	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplantation, 2017, 52, 539-543.	2.4	30
98	Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leukemia Research, 2013, 37, 573-579.	0.8	29
99	TRPC3 shapes the ER-mitochondria Ca2+ transfer characterizing tumour-promoting senescence. Nature Communications, 2022, 13, 956.	12.8	29
100	Synthesis and biological evaluation of phenstatin metabolites. Bioorganic and Medicinal Chemistry, 2011, 19, 6042-6054.	3.0	28
101	Administration of alemtuzumab and <scp>G</scp>â€<scp>CSF</scp> to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase <scp>II</scp> study. European Journal of Haematology, 2013, 91, 315-321.	2.2	28
102	p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood, 2002, 99, 2620-2623.	1.4	27
103	Activity of Ladanein on Leukemia Cell Lines and Its Occurrence inMarrubium vulgare. Planta Medica, 2010, 76, 86-87.	1.3	27
104	CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Medicine, 2019, 8, 1279-1288.	2.8	27
105	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. Blood, 2014, 124, 117-117.	1.4	27
106	p16^{ink4a}Gene and Hematological Malignancies. Leukemia and Lymphoma, 1996, 22, 11-24.	1.3	26
107	Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells. Scientific Reports, 2016, 6, 30405.	3.3	25
108	Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial. Blood, 2017, 130, 889-889.	1.4	25

#	Article	IF	Citations
109	Antifungal and Cytotoxic Activity of Withanolides from Acnistus arborescens. Journal of Natural Products, 2010, 73, 1313-1317.	3.0	24
110	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. Cancers, 2020, 12, 1992.	3.7	24
111	Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica, 2003, 88, 476-8.	3.5	24
112	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Cancer Research, 2014, 74, CT231-CT231.	0.9	23
113	Transfer of p16 inka /CDKN2 gene in leukaemic cell lines inhibits cell proliferation. British Journal of Haematology, 1996, 95, 291-298.	2.5	22
114	Linezolid induces ring sideroblasts. Haematologica, 2013, 98, e138-e140.	3.5	21
115	Monocyte chemoattractant protein 1 (MCPâ€1/CCL2) contributes to thymus atrophy in acute myeloid leukemia. European Journal of Immunology, 2015, 45, 396-406.	2.9	21
116	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood, 2021, 138, 246-246.	1.4	21
117	SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia, 2003, 17, 1678-1679.	7.2	20
118	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget, 2016, 7, 62377-62385.	1.8	20
119	c-mplExpression in Hematologic Disorders. Leukemia and Lymphoma, 1995, 17, 19-26.	1.3	19
120	Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Therapy, 2010, 17, 880-891.	4.5	19
121	Î³-Irradiation enhances transgene expression in leukemic cells. Gene Therapy, 2003, 10, 227-233.	4.5	18
122	Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leukemia Research, 2009, 33, 547-550.	0.8	18
123	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica, 2010, 95, 892-899.	3.5	18
124	Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort. International Journal of Antimicrobial Agents, 2019, 53, 781-788.	2.5	18
125	Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia, 1993, 7, 1888-90.	7.2	18
126	Correspondence. Leukemia Research, 1999, 23, 415-416.	0.8	17

#	Article	IF	Citations
127	Three new cases of non-Hodgkin lymphoma with t(9;14)(p13;q32). Cancer Genetics and Cytogenetics, 2003, 145, 65-69.	1.0	17
128	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leukemia Research, 2011, 35, 448-458.	0.8	17
129	GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation. Biochemical and Biophysical Research Communications, 2016, 478, 513-520.	2.1	16
130	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia, 2016, 30, 1416-1418.	7.2	16
131	No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study.. Blood, 2005, 106, 15-15.	1.4	16
132	An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica, 2006, 91, 1134-8.	3.5	16
133	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplantation, 2002, 30, 229-234.	2.4	15
134	Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients. Annals of Oncology, 2001, 12, 1749-1755.	1.2	14
135	Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitorâ€like state. Journal of Cellular Biochemistry, 2011, 112, 1277-1285.	2.6	14
136	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood, 2019, 134, 2414-2416.	1.4	14
137	Multiple myeloma: all roads lead to cyclin D. Blood, 2005, 106, 1-2.	1.4	13
138	Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia, 2007, 21, 2376-2377.	7.2	13
139	CAR T-cells: A John von Neumann legacy?. Current Research in Translational Medicine, 2018, 66, 35-36.	1.8	13
140	Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.. Blood, 2009, 114, 843-843.	1.4	13
141	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). Blood, 2010, 116, 2183-2183.	1.4	13
142	Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica, 2000, 85, 502-7.	3.5	13
143	Acute Myocarditis Induced by Hypomethylating Agents. Journal of Clinical Oncology, 2011, 29, e411-e412.	1.6	12
144	Tumor Dormancy: Long-Term Survival in a Hostile Environment. Advances in Experimental Medicine and Biology, 2013, 734, 181-200.	1.6	12

#	Article	IF	Citations
145	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. European Journal of Cancer, 2014, 50, 196.	2.8	12
146	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	1.4	12
147	Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1994, 8, 878-80.	7.2	12
148	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. Leukemia and Lymphoma, 2004, 45, 2481-2484.	1.3	11
149	Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology. BMC Cancer, 2018, 18, 1219.	2.6	11
150	Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction. European Journal of Medicinal Chemistry, 2022, 236, 114343.	5.5	11
151	Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?. Expert Review of Vaccines, 2006, 5, 773-781.	4.4	10
152	Humulane and Germacrane Sesquiterpenes from Ferula lycia. Journal of Natural Products, 2010, 73, 780-783.	3.0	10
153	Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs. International Journal of Biochemistry and Cell Biology, 2017, 85, 166-174.	2.8	10
154	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. Blood, 2010, 116, 439-439.	1.4	10
155	Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST). Bio-protocol, 2020, 10, e3574.	0.4	10
156	In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. Journal of Obstetrics and Gynaecology Research, 2006, 32, 449-453.	1.3	9
157	A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. Molecular Cancer, 2011, 10, 105.	19.2	9
158	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 2012, 36, 1112-1118.	0.8	9
159	Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leukemia Research, 2012, 36, 1330-1333.	0.8	9
160	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.8	9
161	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700178.	6.7	9
162	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. Blood, 2018, 132, 467-467.	1.4	9

#	Article	IF	Citations
163	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. Leukemia, 2001, 15, 1054-1059.	7.2	8
164	A case of refractory anemia with 17pâ" syndrome following azathioprine treatment for heart transplantation. Leukemia, 2004, 18, 878-878.	7.2	8
165	Efficient generation of antileukemic autologous T cells by short-term culture and ?-irradiation of myeloid leukemic cells. Cancer Immunology, Immunotherapy, 2004, 53, 793-8.	4.2	8
166	Induction of leukemia-specific CD8+ cytotoxic t cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-Î±. Molecular Therapy, 2005, 11, 950-959.	8.2	8
167	Repression of the RHOH gene by JunD. Biochemical Journal, 2011, 437, 75-88.	3.7	8
168	Acute Myeloid Leukemia: Is It T Time?. Cancers, 2021, 13, 2385.	3.7	8
169	Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia, 1993, 7, 1071.	7.2	8
170	Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities. Leukemia and Lymphoma, 2002, 43, 1819-1822.	1.3	7
171	Short-term culture of myeloid leukemic cells allows efficient transduction by adenoviral vectors. Journal of Gene Medicine, 2004, 6, 751-759.	2.8	7
172	Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes. Current Research in Translational Medicine, 2017, 65, 77-81.	1.8	7
173	Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. Journal of Visualized Experiments, 2018, , .	0.3	7
174	Modulation of the Gal-9/TIM-3 Immune Checkpoint with Î±-Lactose. Does Anomery of Lactose Matter?. Cancers, 2021, 13, 6365.	3.7	7
175	Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3368.	3.7	7
176	Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size. Leukemia Research Reports, 2020, 13, 100202.	0.4	6
177	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Medicine, 2021, 10, 6336-6343.	2.8	6
178	Methylation and myelodysplastic syndromes: When and where?. Leukemia Research, 2006, 30, 1327-1329.	0.8	5
179	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hautsâ€deâ€France AML observatory. American Journal of Hematology, 2019, 94, E24-E27.	4.1	5
180	Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion Abilities. Stem Cells and Development, 2020, 29, 919-928.	2.1	5

#	Article	IF	Citations
181	Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients. The Hematology Journal, 2001, 2, 81-86.	1.4	5
182	Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.. Blood, 2009, 114, 1054-1054.	1.4	5
183	Role of IRF4 in resistance to immunomodulatory (IMid) compoundsÂ® in WaldenstrÃ¶mâ€™s macroglobulinemia. Oncotarget, 2017, 8, 112917-112927.	1.8	5
184	Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. International Journal of Molecular Sciences, 2022, 23, 5555.	4.1	5
185	Modelling a regional reorganization of cardiovascular surgery provision. Health and Place, 2005, 11, 283-292.	3.3	4
186	MEK inhibitor: the MM magic bullet?. Blood, 2007, 110, 1402-1403.	1.4	4
187	Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.. Blood, 2006, 108, 2666-2666.	1.4	4
188	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 163-163.	1.4	4
189	Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML). Blood, 2013, 122, 2796-2796.	1.4	4
190	De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory. Blood, 2016, 128, 4013-4013.	1.4	4
191	Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2022, 101, 1321-1331.	1.8	4
192	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. Journal of Clinical Medicine, 2021, 10, 1162.	2.4	3
193	Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program. Blood, 2008, 112, 2682-2682.	1.4	3
194	Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) â‰¥ 80 Years: Results of the French ATU Program.. Blood, 2009, 114, 1773-1773.	1.4	3
195	FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes. Blood, 2010, 116, 232-232.	1.4	3
196	Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML. Blood, 2010, 116, 3997-3997.	1.4	3
197	Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group. Blood, 2010, 116, 505-505.	1.4	3
198	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2012, 120, 422-422.	1.4	3

#	Article	IF	Citations
199	ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular Metabolism, 2021, 55, 101410.	6.5	3
200	Pairing cells of different sizes in a microfluidic device for immunological synapse monitoring. Lab on A Chip, 2022, 22, 908-920.	6.0	3
201	Put in a â€œCa2+llâ€•to Acute Myeloid Leukemia. Cells, 2022, 11, 543.	4.1	3
202	p65/RelA NFâ€ÎºB fragments generated by RIPK3 activity regulate tumorigenicity, cell metabolism, and stemness characteristics. Journal of Cellular Biochemistry, 2022, 123, 543-556.	2.6	3
203	Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients. Cancers, 2021, 13, 6353.	3.7	3
204	A NEW CASE OF THERAPY-RELATED ACUTE MYELOID LEUKAEMIA WITH t(8;16)(p11;p13). British Journal of Haematology, 1998, 100, 801-802.	2.5	2
205	TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. Annales De GÃ©nÃ©tique, 2002, 45, 165-168.	0.4	2
206	Methyltransferases in myelodysplastic syndromes: Guilty or not guilty?. Leukemia Research, 2009, 33, 601-602.	0.8	2
207	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with lowâ€“intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leukemia and Lymphoma, 2010, 51, 1668-1677.	1.3	2
208	Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM. Blood, 2008, 112, 2672-2672.	1.4	2
209	MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia. Blood, 2012, 120, 1307-1307.	1.4	2
210	Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM). Blood, 2012, 120, 297-297.	1.4	2
211	Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA). Blood, 2014, 124, 482-482.	1.4	2
212	BACH2 promotes indolent clinical presentation in WaldenstrÃ¶m macroglobulinemia. Oncotarget, 2017, 8, 57451-57459.	1.8	2
213	Expanded Access Program: Evaluating Safety of Erythrocytes Encapsulating L-Asparaginase in Combination with Polychemotherapy in Patients Under 55 Years Old with Acute Lymphoblastic Leukaemia (ALL) at Risk to Receive Other Formulations of Asparaginase. Blood, 2021, 138, 1214-1214.	1.4	2
214	Chemotherapy increases transgene expression in leukemic cells. Journal of Gene Medicine, 2003, 5, 852-859.	2.8	1
215	220 ACETAMINOPHEN THERAPEUTIC MISADVENTURE: A PROSPECTIVE STUDY. Journal of Hepatology, 2008, 48, S91.	3.7	1
216	Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity. Immunology Letters, 2017, 192, 27-34.	2.5	1

#	Article	IF	Citations
217	Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia, 2020, 34, 2230-2233.	7.2	1
218	Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy. EJHaem, 2021, 2, 196-210.	1.0	1
219	RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.. Blood, 2006, 108, 2661-2661.	1.4	1
220	Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2011, 118, 972-972.	1.4	1
221	The B7-H3 Protein In Acute Myeloid Leukemia. Blood, 2013, 122, 2620-2620.	1.4	1
222	Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis. Blood, 2014, 124, 1083-1083.	1.4	1
223	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327.	1.4	1
224	Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650). Blood, 2015, 126, 4877-4877.	1.4	1
225	Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup. Blood, 2008, 112, 553-553.	1.4	1
226	Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA). Blood, 2011, 118, 253-253.	1.4	1
227	Dormance tumorale: quiescence ouÂÃ©quilibre?. Hematologie, 2010, 16, 355-362.	0.0	0
228	Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.. Blood, 2005, 106, 1862-1862.	1.4	0
229	Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.. Blood, 2007, 110, 1849-1849.	1.4	0
230	Long-Term Survival Analysis in Older Patients with AML Treated Intensively: Positive Impact of Idarubicin in a Cure Fraction Estimation Model.. Blood, 2008, 112, 960-960.	1.4	0
231	Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.. Blood, 2009, 114, 3820-3820.	1.4	0
232	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. Blood, 2010, 116, 2171-2171.	1.4	0
233	AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM). Blood, 2010, 116, 2911-2911.	1.4	0
234	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. Blood, 2010, 116, 4171-4171.	1.4	0

#	Article	IF	Citations
235	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. Blood, 2010, 116, 3996-3996.	1.4	0
236	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	1.4	0
237	B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstroî‚m Macroglobulinemia. Blood, 2012, 120, 1288-1288.	1.4	0
238	Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification. Blood, 2012, 120, 3843-3843.	1.4	0
239	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€“ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. Blood, 2013, 122, 495-495.	1.4	0
240	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. Blood, 2013, 122, 2753-2753.	1.4	0
241	AML At First Relapse: A Real Life Picture. Blood, 2013, 122, 3895-3895.	1.4	0
242	Abstract 1342: RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. , 2014, , .		0
243	Epidemiology of Adults AML in Nord-Pas De Calais and Picardy. Blood, 2014, 124, 2281-2281.	1.4	0
244	Monitoring of Wilmsâ€™ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1265-1265.	1.4	0
245	Abstract 3216: Immunogenicity and genomic profiling reveal sub-clonal diversity of a murine acute myeloid leukemia (AML) cell line. , 2015, , .		0
246	Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group. Blood, 2015, 126, 2568-2568.	1.4	0
247	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. Blood, 2019, 134, 853-853.	1.4	0
248	Systemic injection of GM-CSF increases survival in a murine model of acute leukemia. Haematologica, 2002, 87, ELT13.	3.5	0
249	Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity. PLoS ONE, 2022, 17, e0267508.	2.5	0
250	Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents. Leukemia Research, 2022, 118, 106871.	0.8	0